sertraline
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive Compulsive Disorder
Conditions
Obsessive Compulsive Disorder
Trial Timeline
Apr 4, 2012 → Sep 9, 2020
NCT ID
NCT01302080About sertraline
sertraline is a pre-clinical stage product being developed by Pfizer for Obsessive Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01302080. Target conditions include Obsessive Compulsive Disorder.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01302080 | Pre-clinical | Completed |
| NCT00585455 | Pre-clinical | Terminated |
| NCT00245557 | Pre-clinical | Completed |
| NCT02122393 | Phase 3 | Completed |
| NCT00118014 | Approved | Completed |
Competing Products
17 competing products in Obsessive Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine | Eli Lilly | Approved | 85 |
| Fluvoxamine maleate + Placebo | AbbVie | Phase 3 | 77 |
| quetiapine fumarate + SSRI/Clomipramine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo) | Novartis | Approved | 85 |
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 52 |
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram | Lundbeck | Approved | 82 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| RG1068 (Synthetic Human Secretin) | Repligen | Phase 2 | 49 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 60 |
| Troriluzole (BHV-4157) | Biohaven | Phase 3 | 72 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |